Targeted radiopharmaceutical therapy for advanced lung cancer: Phase i trial of rhenium Re188 P2045, a somatostatin analog

Journal of Thoracic Oncology

Volumn 4, Issue 12, 2009, Pages 1550-1554

  Edelman, Martin J ^a   Clamon, Gerry ^b   Kahn, Daniel ^c   Magram, Martin ^d   Lister James, John ^e   Line, Bruce R ^d  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Antisoma Inc   (United States)

Author keywords

Lung cancer; Rhenium; Somatostatin analog; Targeted therapy

Indexed keywords

P2045 PEPTIDE RE 188; P2045 PEPTIDE TC 99M; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; HUMAN; HYPONATREMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RECURRENT CANCER; SINGLE DRUG DOSE; SURVIVAL TIME;

EID: 74249087483     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181bf1070     Document Type: Article

References (12)

1. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S- 66S.
2. Menda Y, Kahn D. Somatostatin receptor imaging in non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med 2002;32:92-96.
3. Kwekkeboom DJ, Krenning EP, Bakker WH, et al. Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. J Nucl Med 1991;32:1845-1848.
4. Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 1994;55:1797-1806.
5. O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP. Somatostatin, its receptor and analogs in lung cancer. Chemotherapy 2001; 47(Suppl 2):78-108.
6. Dizeyi N, Konrad L, Wu H, et al. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002;7:91-98.
7. Kumar U, Grigorakis SI, Watt HL, et al. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005;92:175-186.
8. Cyr JE, Pearson DA, Wilson DM, et al. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J Med Chem 2007;50:1354-1364.
9. Magram MY, Edelman MJ, LoBuglio AF, et al. A Novel radiolabelled somatostatin receptor targeting peptide, P2045, as a potential targeted therapy for lung cancer. J Nucl Med 2003;44(Suppl 5):137P.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
11. Pfister DG, Johnson DH, Azzoli CG, et al; American Society of Clinical Oncology. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
12. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993;67:1437-1439.